Why the study?
Heart failure prognosis has been reported similar across preserved vs reduced LVEF, prompting this comparison of long-term prognosis among heart failure subtypes undergoing RFCA for AF.
Does long-term prognosis after radiofrequency catheter ablation for atrial fibrillation differ among heart failure subtypes based on left ventricular ejection fraction?
Does long-term prognosis after radiofrequency catheter ablation for atrial fibrillation differ among heart failure subtypes based on left ventricular ejection fraction?
Patients with HFrEF and AF have an approximately three times higher risk of adverse cardiovascular events after AF ablation compared to those with HFmrEF or HFpEF, despite similar arrhythmia recurrence rates.
HFpEF patients post-AF ablation warrant closer monitoring than assumed; leaves open LVEF-specific ablation benefit in prospective trials.
AIMS: Heart failure (HF) prognosis has been reported similar in patients with preserved vs. reduced left ventricular ejection fraction (LVEF). This study compared the long-term prognosis of HF patients undergoing radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF). METHODS AND RESULTS: Among 5010 patients undergoing RFCA in Kansai Plus AF registry, 656 patients (13.1%) with a documented history of HF were enrolled in the study before RFCA. The primary endpoint was a composite of all-cause death, HF hospitalization, and stroke or systemic embolism. Patients with reduced (<40%), mid-range (40-49%), and preserved (≥50%) LVEF were 98 (14.9%), 107 (16.3%), and 451 (68.8%) patients, respectively. The prevalence of ischaemic heart disease and cardiomyopathies was higher among patients with reduced as compared with preserved LVEF (27.6% vs. 10.0%, P < 0.05 and 36.7% vs. 15.3%, P < 0.05, respectively). The median follow-up period was 2.9 years. The 3-year cumulative risk for the primary endpoint was higher in patients with reduced LVEF (32.7%) compared to those with mid-range (11.7%) or preserved (11.6%) LVEF (P < 0.001). Reduced LVEF was the most significant independent risk factor for primary endpoint (hazard ratio, 2.83; 95% confidence interval 1.74-4.61, P < 0.001). The 3-year arrhythmia recurrence rate was similar among the groups (48.2%, 42.8%, and 47.3%, respectively, P = 0.75). CONCLUSION: This study raises hypothesis that patients with HFrEF and AF had approximately three times higher risk for a composite of all-cause death, HF hospitalization, and stroke or systemic embolism after AF ablation compared with patients with HFmrEF or HFpEF.
No takes yet. Share an insight, caveat, or question.
Fujimoto et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: